Recent studies have revealed that somatic mutations are detected in approximately 30% of AA patients, and mutations in several genes such as DNMT3A, ASXL1, and RUNX1 are associated with secondary myeloid malignancies [14, 26]. Here, RUNX1 is linked to myeloid neoplasm.